Table 1

Patient characteristics

All patientsPatients with inflammatory disease (n=40)Patients with non-inflammatory disease (n=28)
Sex41.2% female (28/68)27.5% female (11/40)60.71% female (17/28)
Age40.54±12.2339.85 (SD 12.23)41.54 (SD 11.96)
HLA-B27 positivity55.8% (29/52)73.33% (22/30)21.82% (7/22)
Mean CRP12.34 (n=24)14.89 (SD 17.78; n=15)7.58 (SD 18.38; n=9)+negative in 3 patients
BASDAI4.67±1.61 (n=33)4.6 (SD 1.61; n=27)5.02 (SD 1.61; n=6)
Modified New York Criteria positivityN/A52.5% (21/40)N/A
ASAS MRI criteria positivityN/A52.5% (21/40)N/A
Erosion sum score2.05 (SD 3.37)3.16 (SD 3.37)0.46 (SD 3.29)
Sclerosis sum score2.87 (SD 3.09)3.26 (SD 3.09)2.31 (SD 3.03)
Joint space sum score2.26 (SD 3.26)3.53 (SD 3.26)0.45 (SD 3.24)
  • Patient characteristics are presented for all patients and by subgroup according to the rheumatologist’s final diagnosis (inflammatory vs non-inflammatory disease) by the rheumatologist. Inflammatory conditions were axial spondyloarthritis (axSpA) (n=35; r-axSpA: n=29, nr-axSpA: n=6), psoriatic arthritis with axial inflammation (n=4) and SAPHO (n=1). Non-inflammatory conditions were degenerative spine disease (n=14), osteitis condensans ilii (n=13) and psoriatic arthritis without axial involvement (n=1). The sum scores are mean scores in CT.

  • ASAS, Assessment of SpondyloArthritis international Society; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; SAPHO, synovitis, acne, pustulosis, hyperostosis and synovitis syndrome.